The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Improving Cancer Management By Direct Detection With Diffusion-weighted Magnetic Resonance Imaging.
Funder
National Health and Medical Research Council
Funding Amount
$421,549.00
Summary
Despite reliable methods of prostate and breast cancer diagnosis there remains considerable uncertainty as to whether the detected disease will have a significant impact on a patient’s quality of life. This uncertainty is largely due to the inability of current detection methods to show the extent of disease. This project will address this problem by developing new MRI methods that directly measure the microscopic tissue properties that define cancer.
Modelling Epigenomic Change During Early Breast Carcinogenesis Using In Vitro And In Vivo Model Systems
Funder
National Health and Medical Research Council
Funding Amount
$743,360.00
Summary
Epigenetics describes how genes can be turned on and off without a change in the DNA sequence. Epigenetic changes are common and often occur early in cancer, but we do not know where or how epigenetic changes occur in cancer. In this proposal we will create the first detailed map of the epigenetic landscape of normal and cancer breast cells. These maps will allow us to predict where epigenetic lesions occur in breast cancer, which will have important diagnostic and therapeutic value for cancer t ....Epigenetics describes how genes can be turned on and off without a change in the DNA sequence. Epigenetic changes are common and often occur early in cancer, but we do not know where or how epigenetic changes occur in cancer. In this proposal we will create the first detailed map of the epigenetic landscape of normal and cancer breast cells. These maps will allow us to predict where epigenetic lesions occur in breast cancer, which will have important diagnostic and therapeutic value for cancer treatments.Read moreRead less
A Functional Assay To Classify Genetic Variants In Lynch Syndrome
Funder
National Health and Medical Research Council
Funding Amount
$368,195.00
Summary
At least one person in every 1000 is affected by Lynch syndrome, in which faulty DNA repair machinery causes high rates of cancer. People with Lynch syndrome can have their risk of cancer cut substantially with regular screening. However, we often struggle to understand whether people with 'non-standard' DNA sequences in particular genes actually have Lynch syndrome. This project develops a simple test that will tell clinicians whether a given sequence change relates to Lynch syndrome or not.
Targeting Activated Platelets: A Novel Innovative Approach For The Sensitive Detection And Therapeutic Targeting Of Various Cancers And Their Metastases
Funder
National Health and Medical Research Council
Funding Amount
$948,447.00
Summary
Early detection and selective therapy is critical for the survival of patients with cancer. We have shown in pilot experiments that platelets accumulate at the site of tumours and thus provide the opportunity to diagnose and localise cancer and its metastases. Based on this and also newly developed biotechnological tools we aim to develop multiple innovative imaging technologies. Furthermore, we will develop novel tumour-targeted and thus tumour site-specific, side-effect poor cancer treatments.
Molecular Characterisation Of Early Precursor Lesions Of A Novel Ñserrated Pathwayî Of Colorectal Cancer Using Gene Expression And Proteomics.
Funder
National Health and Medical Research Council
Funding Amount
$318,338.00
Summary
In Australia, CRC is the second highest cause of all cancer-related deaths. If detected early, CRC has a high success rate of cure, but a percentage of precursor lesions escape detection and show aggressive clinical behaviour to progress to CRC. These are difficult to diagnosis with existing technologies. We aim to understand the biology behind sessile serrated adenoma pathways and hence enhance early detection, diagnosis and treatments strategies.
PET Imaging Agents For The Differential Diagnosis Of Hypoxic Tumors
Funder
National Health and Medical Research Council
Funding Amount
$585,429.00
Summary
Choosing the best type of treatment from the ever increasing arsenal of chemotherapeutic agents against cancer is of critical importance. Tumor hypoxia requires specialized treatment and patient selection. Current PET imaging agents cannot differentiate between severely and mildly hypoxic tumors. We have found a new agent that can detect mildly hypoxic tumors and the aim of this grant application is to further develop this radiotracer to improve image quality and reliability of the diagnosis.
Establishment Of A Biomarker To Test Molecular Risk Of Gastric Cancer
Funder
National Health and Medical Research Council
Funding Amount
$834,448.00
Summary
Less than 20% of patients live 5 years after a diagnosis of gastric cancer (GC). This is due to the advanced stage at the time of diagnosis. We have no markers to monitor therapy of cancer. This proposal aims to use next generation sequencing to find specific genetic changes in a persons tumour that can be used to monitor therapy. We aim to use the same technology to group patients into high-risk or low risk for development of GC. This will allow specific screening only for those at high-risk.